Althea Technologies Inc has entered into an agreement with Baxter Healthcare Corporation and Baxter Pharmaceutical Solutions, LLC to co-promote Althea's plasmid DNA manufacturing services and each company's contract fill and finish services.
The goal of this agreement is to provide to companies that are developing plasmid DNA vaccines and other biologics with a solution for their manufacturing and clinical packaging needs from the preclinical stage through commercialization. Althea and Baxter will provide the services in their areas of specialization to better assist the customers with their development and clinical trial needs.
Under the agreement, Althea will provide small batch production and filling capabilities to customers in preclinical through Phase III clinical trials. Baxter Pharmaceutical Solutions, LLC will provide large batch production, packaging and filling services as customers commercialize their products and launch into the market.
"We are extremely pleased to be entering such an agreement with Baxter, a leading supplier of clinical packaging services," stated Rick Hancock, senior vice president of operations of Althea. "Our strength is to provide production and filling capabilities to customers in preclinical through Phase III clinical trials. We believe that referring the packaging and filling services to Baxter for large capacity needs will provide our customers with a seamless transition to commercialize their products."